Use of LDH and autoimmune side effects to predict response to ipilimumab treatment
Background: Ipilimumab is a cytotoxic T-lymphocyte antigen-4 antibody that enhances T-cell activity and proliferation. Methods: In a retrospective analysis of 86 patients the clinical benefits of ipilimumab treatment were correlated with laboratory and clinical data. Results: A lactate dehydrogenase...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
3 August 2016
|
| In: |
Immunotherapy
Year: 2016, Volume: 8, Issue: 9, Pages: 1033-1044 |
| ISSN: | 1750-7448 |
| DOI: | 10.2217/imt-2016-0083 |
| Online Access: | Verlag, Volltext: http://dx.doi.org/10.2217/imt-2016-0083 Verlag, Volltext: https://www.futuremedicine.com/doi/abs/10.2217/imt-2016-0083 
|
| Author Notes: | J Dick, N Lang, A Slynko, A Kopp-Schneider, C Schulz, A Dimitrakopoulou-Strauss, AH Enk, and JC Hassel |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1570261768 | ||
| 003 | DE-627 | ||
| 005 | 20220814083325.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180228s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2217/imt-2016-0083 |2 doi | |
| 035 | |a (DE-627)1570261768 | ||
| 035 | |a (DE-576)500261768 | ||
| 035 | |a (DE-599)BSZ500261768 | ||
| 035 | |a (OCoLC)1340992624 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Dick, Julika |d 1983- |e VerfasserIn |0 (DE-588)102042513X |0 (DE-627)691215308 |0 (DE-576)360424155 |4 aut | |
| 245 | 1 | 0 | |a Use of LDH and autoimmune side effects to predict response to ipilimumab treatment |c J Dick, N Lang, A Slynko, A Kopp-Schneider, C Schulz, A Dimitrakopoulou-Strauss, AH Enk, and JC Hassel |
| 264 | 1 | |c 3 August 2016 | |
| 300 | |a 12 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 28.02.2018 | ||
| 520 | |a Background: Ipilimumab is a cytotoxic T-lymphocyte antigen-4 antibody that enhances T-cell activity and proliferation. Methods: In a retrospective analysis of 86 patients the clinical benefits of ipilimumab treatment were correlated with laboratory and clinical data. Results: A lactate dehydrogenase (LDH) value within the normal range before the start of therapy was significantly correlated with better OS (p ≤ 0.009). An increase in LDH level after two cycles was indicative of a poor outcome, and was significantly negatively correlated with treatment response and overall survival and progression-free survival. 42% of all patients suffered from autoimmune toxicity (CTCAE grades 2-4). The occurrence of autoimmune toxicity clearly correlated with clinical benefit. Conclusion: Changes in LDH level and side effects correlate with response to therapy and survival. | ||
| 700 | 1 | |a Lang, Nina |d 1985- |e VerfasserIn |0 (DE-588)143835718 |0 (DE-627)655106057 |0 (DE-576)339275413 |4 aut | |
| 700 | 1 | |a Schulz, Christof |d 1990- |e VerfasserIn |0 (DE-588)1152848607 |0 (DE-627)1014117143 |0 (DE-576)499937597 |4 aut | |
| 700 | 1 | |a Enk, Alexander |d 1963- |e VerfasserIn |0 (DE-588)1032757140 |0 (DE-627)739272535 |0 (DE-576)166173517 |4 aut | |
| 700 | 1 | |a Hassel, Jessica C. |d 1975- |e VerfasserIn |0 (DE-588)129790702 |0 (DE-627)480399069 |0 (DE-576)29783715X |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Immunotherapy |d London : Taylor & Francis, 2009 |g 8(2016), 9, Seite 1033-1044 |h Online-Ressource |w (DE-627)600591891 |w (DE-600)2495964-9 |w (DE-576)398101108 |x 1750-7448 |7 nnas |a Use of LDH and autoimmune side effects to predict response to ipilimumab treatment |
| 773 | 1 | 8 | |g volume:8 |g year:2016 |g number:9 |g pages:1033-1044 |g extent:12 |a Use of LDH and autoimmune side effects to predict response to ipilimumab treatment |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2217/imt-2016-0083 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://www.futuremedicine.com/doi/abs/10.2217/imt-2016-0083 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180228 | ||
| 993 | |a Article | ||
| 994 | |a 2016 | ||
| 998 | |g 129790702 |a Hassel, Jessica C. |m 129790702:Hassel, Jessica C. |d 910000 |d 911300 |e 910000PH129790702 |e 911300PH129790702 |k 0/910000/ |k 1/910000/911300/ |p 8 |y j | ||
| 998 | |g 1032757140 |a Enk, Alexander |m 1032757140:Enk, Alexander |d 910000 |d 911300 |e 910000PE1032757140 |e 911300PE1032757140 |k 0/910000/ |k 1/910000/911300/ |p 7 | ||
| 998 | |g 1152848607 |a Schulz, Christof |m 1152848607:Schulz, Christof |d 910000 |d 910200 |e 910000PS1152848607 |e 910200PS1152848607 |k 0/910000/ |k 1/910000/910200/ |p 5 | ||
| 998 | |g 143835718 |a Lang, Nina |m 143835718:Lang, Nina |d 910000 |d 911300 |e 910000PL143835718 |e 911300PL143835718 |k 0/910000/ |k 1/910000/911300/ |p 2 | ||
| 998 | |g 102042513X |a Dick, Julika |m 102042513X:Dick, Julika |d 910000 |d 911300 |e 910000PD102042513X |e 911300PD102042513X |k 0/910000/ |k 1/910000/911300/ |p 1 |x j | ||
| 999 | |a KXP-PPN1570261768 |e 3001141433 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"person":[{"display":"Dick, Julika","family":"Dick","given":"Julika","role":"aut"},{"display":"Lang, Nina","family":"Lang","given":"Nina","role":"aut"},{"display":"Schulz, Christof","given":"Christof","role":"aut","family":"Schulz"},{"role":"aut","given":"Alexander","family":"Enk","display":"Enk, Alexander"},{"family":"Hassel","role":"aut","given":"Jessica C.","display":"Hassel, Jessica C."}],"relHost":[{"pubHistory":["1.2009 -"],"origin":[{"publisherPlace":"London ; London","dateIssuedKey":"2009","dateIssuedDisp":"2009-","publisher":"Taylor & Francis ; Future Medicine Ltd"}],"title":[{"title_sort":"Immunotherapy","title":"Immunotherapy"}],"part":{"pages":"1033-1044","issue":"9","extent":"12","text":"8(2016), 9, Seite 1033-1044","year":"2016","volume":"8"},"id":{"eki":["600591891"],"issn":["1750-7448"],"zdb":["2495964-9"]},"note":["Gesehen am 28.05.2024"],"type":{"bibl":"periodical","media":"Online-Ressource"},"language":["eng"],"recId":"600591891","physDesc":[{"extent":"Online-Ressource"}],"disp":"Use of LDH and autoimmune side effects to predict response to ipilimumab treatmentImmunotherapy"}],"origin":[{"dateIssuedDisp":"3 August 2016","dateIssuedKey":"2016"}],"note":["Gesehen am 28.02.2018"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"language":["eng"],"title":[{"title_sort":"Use of LDH and autoimmune side effects to predict response to ipilimumab treatment","title":"Use of LDH and autoimmune side effects to predict response to ipilimumab treatment"}],"physDesc":[{"extent":"12 S."}],"recId":"1570261768","name":{"displayForm":["J Dick, N Lang, A Slynko, A Kopp-Schneider, C Schulz, A Dimitrakopoulou-Strauss, AH Enk, and JC Hassel"]},"id":{"eki":["1570261768"],"doi":["10.2217/imt-2016-0083"]}} | ||
| SRT | |a DICKJULIKAUSEOFLDHAN3201 | ||